trillium-platform
(2)
Jack Hoppin
Jack Hoppin is the co-founder, chairman, and CEO of Ratio Therapeutics, a Boston-based biotech developing targeted radiopharmaceuticals for cancer. A mathematician by training with a PhD in applied mathematics, he previously co-founded the molecular imaging company Invicro and led Konica Minolta Precision Medicine. At Ratio he pairs with scientific co-founder John Babich to build fit-for-purpose radioligand therapies on the company's Trillium pharmacokinetic-modulation and Macropa chelation platforms, backed by investors including Bristol Myers Squibb and a partnership with Novartis.
Ratio Therapeutics
Ratio Therapeutics is a Boston-based clinical-stage biotech engineering next-generation targeted radiopharmaceuticals for solid tumors. Its proprietary Trillium and Macropa platforms tune how radioactive cancer-killing payloads travel through the body, aiming to deliver a lethal dose to tumors while sparing healthy tissue. Backed by major pharma partners including Novartis, Bayer, Lantheus and Bristol Myers Squibb, Ratio is advancing FAP- and SSTR2-targeted programs from imaging into therapy.